TransMedics Group (TMDX) lifted its 2026 revenue outlook after reporting third quarter and year to date results, pointing to stronger than expected performance and earlier contributions from new programs than previously planned.
Investors have been rewarded with sharp recent momentum in TransMedics Group, with a 30 day share price return of 29.10% that aligns with the raised 2026 guidance and latest earnings update. However, the year to date share price return is still down 25.52%, and the 1 year total shareholder return is down 20.55%, compared with a much stronger 5 year total shareholder return of roughly 4x.
Scan beyond TransMedics Group and compare this kind of guidance-driven momentum with a curated list of 35 high quality undervalued stocks that pair strong fundamentals with more conservative pricing.
The recent jump leaves TransMedics Group trading at a double discount, both to analyst targets and to some fair value estimates. Is the market prudently cautious after softer earnings, or too slow to reassess this reset outlook?
On the analyst consensus Narrative on Simply Wall St, TransMedics Group carries a fair value estimate of $102.55 compared with the last close of $91.38, which frames the recent share price rebound against a still implied discount.
The current valuation and analyst price targets indicate that the share price may not fully reflect the potential of a scaled transplant services platform with long-term gross margin goals of roughly 60% and higher transplant volumes than today.
See why 86 investors see TransMedics Group as 11% undervalued.
Result: Fair Value of $102.55 (UNDERVALUED)
Still, the TransMedics Group story could be knocked off course if higher OCS Kidney spending keeps squeezing margins or if legal investigations unsettle investor confidence.
Find out about the key risks to this TransMedics Group narrative.
If this mix of optimism and concern around TransMedics Group feels finely balanced, you may want to act quickly, review the numbers for yourself, and then weigh up the 4 key rewards and 2 important warning signs.
Do not stop with TransMedics Group. Broaden your watchlist using focused stock ideas that match your style, or risk missing opportunities others are already studying.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com